PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Cantanhede, Isabella Gomes ^a   De Oliveira, João Ricardo Mendes ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; TUMOR PROTEIN;

ADULT; AGED; BIOSYNTHESIS; BRAIN TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIGENE FAMILY; NUCLEIC ACID DATABASE; PATHOLOGY;

ADULT; AGED; BRAIN NEOPLASMS; DATABASES, NUCLEIC ACID; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM PROTEINS; PLATELET-DERIVED GROWTH FACTOR;

EID: 85033566704     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-15045-w     Document Type: Article

References (44)

1. Urbanska, K., Sokolowska, J., Szmidt, M. & Sysa, P. Glioblastoma multiforme-An overview. Wspolczesna Onkol. 18, 307-312 (2014).
2. Omuro, A. & LM, D. Glioblastoma and other malignant gliomas: A clinical review. JAMA 310, 1842-1850 (2013).
3. Vitucci, M., Hayes, D. N. & Miller, C. R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br. J. Cancer 104, 545-553 (2011).
4. Cao, Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol. Med. 19, 460-473 (2013).
5. Nazarenko, I. et al. PDGF and PDGF receptors in glioma. Ups. J. Med. Sci. 117, 99-112 (2012).
6. Paulsson, J., Ehnman, M. & Ostman, A. PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncology. 10, 1695-1708 (2014).
7. Heldin, C.-H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. 11, 97 (2013).
8. Inda, M.-D.-M., Bonavia, R. & Seoane, J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 6, (226-39 (2014).
9. Parker, N. R., Khong, P., Parkinson, J. F., Howell, V. M. & Wheeler, H. R. Molecular heterogeneity in glioblastoma: potential clinical implications. Front. Oncol. 5, 55 (2015).
10. Molenaar, R. J. et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro. Oncol. 16, 1263-1273 (2014).
11. Ohno, M. et al. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Jpn. J. Clin. Oncol. 46, 31-39 (2016).
12. Ening, G., Osterheld, F., Capper, D., Schmieder, K. & Brenke, C. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J. Cancer Res. Clin. Oncol. 141, 1131-1137 (2015).
13. Xu, J., Li, Z., Wang, J., Chen, H. & Fang, J. Y. Combined PTEN mutation and protein expression associate with overall and disease-free survival of glioblastoma patients. Transl. Oncol. 7, 196-205 (2014).
14. Chen, J.-R., Yao, Y., Xu, H.-Z. & Qin, Z.-Y. Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas. Medicine (Baltimore). 95, e2583 (2016).
15. Sano, T. et al. Differential Expression of MMAC/PTEN in Glioblastoma Multiforme: Relationship to Localization and Prognosis Advances in Brief Differential Expression of MMAC/PTEN in Glioblastoma Multiforme: Relationship to Localization and Prognosis 1. Cancer Res. 1820-1824 (1999).
16. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
17. Gont, A. et al. PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget 4, 1266-79 (2013).
18. Jung, V. et al. Evidence of Focal Genetic Microheterogeneity in Glioblastoma Multiforme by Area-Specific CGH on Microdissected Tumor Cells. J. Neuropathol. Exp. Neurol. 58, 993-999 (1999).
19. Parker, N. R. et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci. Rep. 6, 22477 (2016).
20. Kumar, A. et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 15, 530 (2014).
21. de Aquino, P. F. et al. A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme. Front. Oncol. 6, 1-10 (2016).
22. Hoelzinger, D. B. et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7, 7-16 (2005).
23. Lemée, J.-M., Clavreul, A. & Menei, P. Intratumoral heterogeneity in glioblastoma: Don't forget the peritumoral brain zone. Neuro. Oncol. 17, 1322-1332 (2015).
24. Meyer, M. et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc. Natl. Acad. Sci. USA 112, 851-856 (2015).
25. Harada, K. et al. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res. 58, 4694-4700 (1998).
26. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
27. Nickel, G. C. et al. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One 7, 1-8 (2012).
28. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110, 4009-4014 (2013).
29. Little, S. E. et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 72, 1614-1620 (2012).
30. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011).
31. Okada, Y. et al. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res. 63, 413-416 (2003).
32. Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. 109, 3041-3046 (2012).
33. Hermansson, M. et al. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc. Natl. Acad. Sci. USA 85, 7748-52 (1988).
34. Hermanson, M. et al. Platelet-derived Growth Factor and Its Receptors in Human Glioma Tissue: Expression of Messenger RNA and Protein Suggests the Presence of Autocrine and Paracrine Loops. Cancer Res. 52, 3213-3219 (1992).
35. Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A. & Giese, N. A. Platelet-derived Growth Factor (PDGF) Autocrine Signaling Regulates Survival and Mitogenic Pathways in Glioblastoma Cells. Cancer Res. 62, 3729-3735 (2002).
36. Kim, Y. et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 26, 1247-1262 (2012).
37. Uhrbom, L., Hesselager, G., Nister, M. & Westermark, B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58, 5275-5279 (1998).
38. Shih, A. H. et al. Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis. Cancer Res. 64, 4783-4789 (2004).
39. Funa, K. & Sasahara, M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J. Neuroimmune Pharmacol. 9, 168-181 (2014).
40. Smoll, N. R., Schaller, K. & Gautschi, O. P. Long-term survival of patients with glioblastoma multiforme (GBM). J. Clin. Neurosci. 20, 670-675 (2013).
41. Duan, S. et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun. 6, 10068 (2015).
42. Verhaak, R. G. W. et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
43. Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803-820 (2016).
44. Verhaak, R. G. W. Moving the needle: Optimizing classification for glioma. Sci. Transl. Med. 8, 350fs14 (2016).